Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
Status:
Terminated
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
This pilot phase I/II trial studies the side effects and how well sirolimus and mycophenolate
mofetil work in preventing graft versus host disease (GvHD) in patients with hematologic
malignancies undergoing hematopoietic stem cell transplant (HSCT). Biological therapies, such
as sirolimus and mycophenolate mofetil, use substances made from living organisms that may
stimulate or suppress the immune system in different ways and stop tumor cells from growing.
Giving sirolimus and mycophenolate mofetil after hematopoietic stem cell transplant may be
better in preventing graft-versus-host disease.